CG Oncology
Updated: December 30, 2025
Arthur Kuan, CEO
Country: USA | Funding: $555.6M (+)
Founded: 2010
Website: https://www.cgoncology.com/
CG Oncology develops oncolytic immunotherapies for patients with advanced bladder cancer. Its flagship drug Cretostimogen is an intravesically administered oncolytic immunotherapy with a dual mechanism of action. It selectively replicates and lyses bladder cancer cells. The rupture of cancer cells can then release tumor-derived antigens, along with GM-CSF, which can stimulate a systemic antitumor immune response involving the body's immune system. CG Oncology has a robust clinical trial program with a developed pipeline to study the safety and efficacy of Cretostimogen. It has received FSA Fast Track and Breakthrough Therapy designations from the FDA.
Founded: 2010
Website: https://www.cgoncology.com/
CG Oncology develops oncolytic immunotherapies for patients with advanced bladder cancer. Its flagship drug Cretostimogen is an intravesically administered oncolytic immunotherapy with a dual mechanism of action. It selectively replicates and lyses bladder cancer cells. The rupture of cancer cells can then release tumor-derived antigens, along with GM-CSF, which can stimulate a systemic antitumor immune response involving the body's immune system. CG Oncology has a robust clinical trial program with a developed pipeline to study the safety and efficacy of Cretostimogen. It has received FSA Fast Track and Breakthrough Therapy designations from the FDA.
